After Hours Summary: AKAM +11%, IRBT +6%, MKSI / KRA / RGC +4% higher and ACHC -18%, AMD -12%, MANH -11%, CMG -9.5%, EW / JNPR -7% lower following earnings/guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AKAM +11.3%, IRBT +5.7%, USNA +4.8%, MKSI +4.2%, KRA +4.1%, RGC +3.7%, NUVA +2.8%, AMED +2.1%, VNOM +1.8%, (light volume), BXMT +1.5% (ticking higher), ILMN +0.6%, MRCY +0.3%, F WB +0.2% (also commences $700 mln offering of convertible senior notes due 2022)
Companies trading higher in after hours in reaction to news: BONT +6.4% (after closing near highs on credit facility update), ALDX +4.8% (initiated after the close with Overweight ratings and $22 tgt at Cantor Fitzgerald), SENS +3.3% (continued strength), TNDM +2.2% (to make any new features approved for the t:slim X2 Insulin Pump by the FDA in 2018 available to all in-warranty users at no cost through the Tandem Device Updater), AMC +1.4% and CNK +0.4% (following RGC results), OSTK +0.8% (extending today's move higher after confirming key details on tZERO's ICO at Money 20/20)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: ACHC -18.4%, AMD -11.6%, MANH -10.8%, CMG -9.5%, EW -6.8%, JNPR -6.6%, VICR -6.3%, SFLY -3.6%, NBR -2.8%, TXN -1.8%, T -1.5%
Companies trading lower in after hours in reaction to news: SNSS -13.5% (commences offering of common stock and Series D Convertible Preferred Stock), HCM -9.4% (to offer US$262.0 million of ADSs), IDRA -7.3% (commences $60 mln common stock offering), SALT -6.6% (commences 10 mln common stock offering), BIOA -5.7% (accepted the resignation of Pres/COO Fabrice Orecchioni; will be assuming advisory role through to February 24, 2018), ATNM -4.2% (indicated lower after filing for $200 mln mixed securities shelf offering and $75 mln ATM under 424B3), PFLT -3.8% (to offer 6 mln shares of common stock in public offering), SVRA -2.1% (announces its indication expansion strategy of its lead product candidate Molgradex for the treatment of nontuberculous mycobacterial lung infection; commences common stock offering), VRAY -1.4% (raised approx $50 mln through offering), NVDA -0.5% (following AMD / TXN results)